10-Q: Hypha Labs Shifts Focus to Bioreactor, Reports Q2 2026 Results

Hypha Labs, Inc. details its strategic pivot from cannabis testing to mushroom bioreactor development, reporting a net loss for the quarter ended March 31, 2026.

Summary

• Hypha Labs, Inc. has transitioned its business focus from cannabis testing to the research, development, and commercialization of the Hypha Micropearl bioreactor for mushroom production.
• The company reported a net loss of $521,114 for the three months ended March 31, 2026, compared to a net loss of $641,822 for the same period in 2025.
• For the six months ended March 31, 2026, the net loss was $1,042,752, compared to $1,981,463 for the same period in 2025.
• Operating expenses decreased significantly due to a reduction in stock-based compensation and the expensing of deferred offering costs.
• The company has $82,200 in cash and negative working capital of $1,338,365, raising substantial doubt about its ability to continue as a going concern.
• Hypha Labs plans to raise additional funds through equity or debt securities, including a Regulation A offering, to fund bioreactor development and commercial launch.
• The company is exploring potential acquisition targets.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the continued net losses, significant going concern risks, and the default on a promissory note, despite the strategic pivot and some financing activities.

Positives

• Significant decrease in operating expenses, particularly general and administrative expenses, by 74% for the six-month period, largely due to reduced stock-based compensation.
• Professional fees decreased by 47% for the three-month period and 28% for the six-month period, also influenced by reduced stock-based compensation and the expensing of deferred offering costs.
• Net cash provided by financing activities was $244,984 for the six months ended March 31, 2026, compared to a net cash used of $26,732 in the prior year period, indicating successful fundraising efforts.
• The company has secured new debt financing, including $150,000 from convertible notes payable and $102,500 from notes payable during the six months ended March 31, 2026.

Negatives

• The company reported a net loss of $521,114 for the three months ended March 31, 2026, and $1,042,752 for the six months ended March 31, 2026.
• The company has negative working capital of $1,338,365 and an accumulated deficit of $24,692,079 as of March 31, 2026.
• Cash on hand was only $82,200 as of March 31, 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Interest expense increased significantly due to higher note payable and convertible note payable balances.
• A promissory note with a principal balance of $113,850 went into default on March 15, 2026, requiring a new payment agreement and resulting in a default penalty of $44,765.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to negative working capital, accumulated losses, and limited cash on hand.
• The company's ability to fund the development and commercial launch of its bioreactor is dependent on successfully raising additional capital through equity or debt securities, with no assurance of success.
• Additional financing may result in substantial dilution to existing stockholders.
• The company is still in the design and development phase for its bioreactor and plans to seek manufacturing arrangements outside the United States, with no guarantee of timely commercialization.
• The company has a history of debt defaults and modifications, indicating potential financial instability.
• The company has material weaknesses in its internal control over financial reporting, including lack of segregation of duties and formal review processes, and lack of an independent board of directors.

Future Outlook

Hypha Labs intends to continue the design, development, and testing of the Hypha Micropearl bioreactor over the next nine months. The company aims to secure a manufacturing arrangement outside the United States for commercial sale and targets a market launch by the latter part of calendar year 2026. The company also plans to raise additional funds through equity or debt securities, including a Regulation A offering, to support these initiatives and is evaluating potential acquisition targets.

Management Comments

• The company believes its innovative bioreactor technology will disrupt traditional methods of mushroom production and bring lab-quality nutrient ingredients into the home with convenience and efficiency.
• Management acknowledges that the company's cash on hand, negative working capital, and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• Management is actively seeking additional sources of capital to fund short-term operations and complete the development and launch of its bioreactor.

Industry Context

StockSavvy.ai notes that Hypha Labs' strategic shift from cannabis testing to mushroom bioreactor technology reflects a broader trend of companies pivoting to capitalize on emerging markets with perceived higher growth potential. The functional mushroom market is experiencing significant interest, driven by consumer demand for health and wellness products.

Comparison to Industry Standards

• The company's net loss of $521,114 for the quarter and $1,042,752 for the six months is substantial for its current asset base, indicating a high burn rate relative to its financial resources.
• The negative working capital of $1,338,365 and limited cash of $82,200 highlight a significant liquidity challenge compared to industry standards for companies in development stages, which typically aim to maintain a stronger cash buffer.
• The company's reliance on debt financing, including convertible notes with increasing balances and interest expenses, is a common strategy for early-stage companies but carries inherent risks if revenue generation does not materialize as planned.
• The company's disclosure of material weaknesses in internal controls is a concern, as robust internal controls are a fundamental expectation for publicly traded companies, especially those seeking further investment.

Corporate Governance

Legal Proceedings

• There are no material pending legal proceedings to which the company is a party or to which any of its property is subject, nor are there any such proceedings known to be contemplated by governmental authorities.

Related Party Transactions

• Compensation expense of $30,000 and $60,000 incurred for services provided by the sole officer during the three and six months ended March 31, 2026 and 2025, respectively.
• As of March 31, 2026, $140,000 was owed to the sole officer for services, and $7,401 in reimbursable expenses were accrued.
• Fees of $10,000 for services provided by directors were accrued as of March 31, 2026.
• 2,000,000 shares of common stock were granted to the sole officer as compensation during the six months ended March 31, 2026, with a fair value of $48,800.
• These transactions may not have been conducted on an arms-length basis.

Stakeholder Impact

• Existing shareholders face potential dilution from future capital raises.
• Creditors may be concerned about the company's ability to meet its debt obligations due to going concern issues and past defaults.
• Employees and consultants may be impacted by the company's financial instability and potential need for further restructuring.
• Suppliers may face extended payment terms or increased risk of non-payment given the company's liquidity challenges.

Next Steps

• Continue design, development, and testing of the Hypha Micropearl bioreactor over the next nine months.
• Seek to enter into a manufacturing arrangement outside the United States for commercial sale of the bioreactor.
• Market the Hypha Micropearl bioreactor by the latter part of calendar year 2026.
• Raise funds through equity or debt securities, including a Regulation A offering.
• Evaluate future investments into potential acquisition targets.

Key Dates

Recommendation

The company is undergoing a significant strategic shift and faces substantial going concern risks. While there is potential in the new bioreactor business, the current financial situation and past defaults warrant a cautious approach. A 'hold' recommendation reflects the uncertainty and the need for further evidence of successful fundraising and operational progress before considering a buy.

Keywords

Hypha Labs, Form 10-Q, Bioreactor, Mushroom Production, Cannabis Testing, Net Loss, Going Concern, Financing, Regulation A Offering, Stock-Based Compensation, Debt Default